Ling Eng Tan

Ling Eng Tan

Auto-generated profile, based on publicly available information

Ling Eng Tan

Ministry of Health, Agency for Care Effectiveness, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
MAMohamed Ismail Abdul Aziz
Mohamed Ismail Abdul Aziz
LTLing Eng Tan
Ling Eng Tan
DWDavid Bin-Chia Wu
David Bin-Chia Wu
FPFiona Pearce
Fiona Pearce
GCGerald Seng Wee Chua
Gerald Seng Wee Chua
KNKwong Ng
Kwong Ng
Purpose: To assess the comparative efficacy of short-acting muscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta-agonists (LABAs; LAMA/LABAs) and inhaled corticosteroids (ICS) in combination with LABA (ICS/LABAs) for the maintenance treatment of COPD. Materials and methods: We systematically reviewed 74 randomized controlled trials (74,832 participants) published up to 15 November 2017, which compared any of the interventions (SAMA [ipratropium], LAMA [aclidinium, glycopyrronium, tiotropium, umeclidinium], LAMA/LABA [aclidinium/formoterol, indacaterol/glycopyrronium, tiotropium/olodaterol, umeclidinium/vilanterol] and ICS/LABA [fluticasone/vilanterol, budesonide/formoterol, salmeterol/fluticasone]) with each other or with placebo. A random-effects network meta-analysis combining direct and indirect evidence was conducted to examine the change from baseline in trough FEV1, transition dyspnea index, St George’s Respiratory Questionnaire and frequency of adverse events at weeks 12 and 24. Results: Inconsistency models were not statistically significant for all outcomes. LAMAs, LAMA/LABAs and ICS/LABAs led to a significantly greater improvement in trough FEV1 compared with placebo and SAMA monotherapy at weeks 12 and 24. All LAMA/LABAs, except aclidinium/formoterol, were statistically significantly better than LAMA monotherapy and ICS/LABAs in improving trough FEV1. Among the LAMAs, umeclidinium showed statistically significant improvement in trough FEV1 at week 12 compared to tiotropium and glycopyrronium, but the results were not clinically significant. LAMA/LABAs had the highest probabilities of being ranked the best agents in FEV1 improvement. Similar trends were observed for the transition dyspnea index and St George’s Respiratory Questionnaire outcomes. There were no significant differences in the incidences of adverse events among all treatment options. Conclusion: LAMA/LABA showed the greatest improvement in trough FEV1 at weeks 12 and 24 compared with the other inhaled drug classes, while SAMA showed the least improvement. There were no significant differences among the LAMAs and LAMA/LABAs within their respective classes.

22 June 2020 in Journal of Medical Economics
Verified
Journal Article
Closed access
MAMohamed Ismail Abdul Aziz
Mohamed Ismail Abdul Aziz
LTLing Eng Tan
Ling Eng Tan
WTWan Hui Gloria Tan
Wan Hui Gloria Tan
CTChee-Keong Toh
Chee-Keong Toh
LLLydia Pui Yee Loke
Lydia Pui Yee Loke
KNKwong Ng
Kwong Ng
Objective: To assess the cost-effectiveness of pembrolizumab monotherapy compared with standard chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in previously untreated adults who have a high programmed death ligand 1 (PD-L1) tumor proportion score of 50% or greater in Singapore. Materials and methods: A partitioned-survival analysis model was developed from a healthcare system’s perspective that extrapolated clinical and economic outcomes of first-line pembrolizumab (maximum treatment duration of 2 years) versus platinum doublet chemotherapy over a 10-year time horizon for patients with advanced NSCLC. The model consisted of 3 health states: alive with no progression, alive with progression and dead. Key clinical inputs were based on Kaplan-Meier survival curves from the interim (median follow-up 11.2 months) and updated analysis (median follow-up 25.2 months) of the KEYNOTE-024 randomized controlled trial. Local cost data were applied. Utilities were derived from published international estimates. Both one-way and multivariate probabilistic sensitivity analyses (PSA) were conducted to identify key drivers of the results. Results: Using the results from the updated analysis of KEYNOTE-024, patients treated with pembrolizumab experienced more quality adjusted life-years (QALYs), but incurred higher costs compared to chemotherapy over a 10-year time horizon (pembrolizumab: 1.9983 QALYs, SGD215,761; chemotherapy: 1.1317 QALYs, SGD70,444). The base-case incremental cost-effectiveness ratio (ICER) was SGD167,692 per QALY gained. One-way sensitivity analysis showed the ICER was most sensitive to the cost of pembrolizumab, followed by the time horizon. Multivariate PSA indicated that pembrolizumab had 0% probability of being cost-effective at a hypothetical willingness-to-pay threshold of SGD100,000 per QALY gained. Conclusion: While pembrolizumab is superior to standard chemotherapy in improving overall survival and progression-free survival, results suggest that it is unlikely to be cost-effective at its current price in Singapore. Factors including clinical effectiveness, safety and budget impact should also be considered when making national funding decisions.

10 November 2020 in Journal of Asthma
Verified
Journal Article
Open access
LTLing Eng Tan
Ling Eng Tan
WTWan Hui Gloria Tan
Wan Hui Gloria Tan
MAMohamed Ismail Abdul Aziz
Mohamed Ismail Abdul Aziz
MKMariko Siyue Koh
Mariko Siyue Koh
TTTunn Ren Tay
Tunn Ren Tay
KNKwong Ng
Kwong Ng
To evaluate the cost-effectiveness of mepolizumab added to standard of care (SOC) compared with SOC alone among patients with severe uncontrolled eosinophilic asthma in the Singapore setting. A Mar...